TapewireFind a company

person · Reporting owner

SCHLEIFER LEONARD S

Disclosed activity across 1 company

Tapewire entity
70475
SEC CIK
0001218629

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
REGENERON PHARMACEUTICALS, INC.REGN · Entity 2010Director · Bd. Co-Chair, President & CEODecember 31, 2025January 05, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

REGENERON PHARMACEUTICALS, INC.

Report date December 31, 2025 · Filed January 05, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect214,523 Ending reported balance After 2025-12-31 transaction · row 2
2 source rows · reconciled sequence

Row 1 · 2025-12-31 · Exercise / conversion · Acquired 28,570 · Balance 243,093

Row 2 · 2025-12-31 · Tax withholding · Disposed 28,570 · Balance 214,523

2020 Performance Stock UnitsSEC Table II · derivative / convertible securityDirect595,077 Reported balance After 2025-12-31 transaction · row 7 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 7 · 2025-12-31 · Exercise / conversion · Disposed 28,570 · Balance 595,077

F1: Each performance restricted stock unit ("PSU") represents a contingent right to receive one share of Company stock. These PSUs were earned during the applicable five-year performance period and vested on December 31, 2025 but remain subject to a mandatory holding period of three years after vesting, which ends early upon the reporting person's death or disability or a change in control of the Company.

Common StockSEC Table I · non-derivativeIndirectBy 2024 GRAT127,484 Reported balance Holding disclosure · report date 2025-12-31 · row 3 Holding and transaction disclosures are not merged.
1 source row

Row 3 · Balance 127,484

Common StockSEC Table I · non-derivativeIndirectBy 2025 GRAT300,000 Reported balance Holding disclosure · report date 2025-12-31 · row 4 Holding and transaction disclosures are not merged.
1 source row

Row 4 · Balance 300,000

Common StockSEC Table I · non-derivativeIndirectBy 401(k) Plan5,989 Reported balance Holding disclosure · report date 2025-12-31 · row 5 Holding and transaction disclosures are not merged.
1 source row

Row 5 · Balance 5,989

Common StockSEC Table I · non-derivativeIndirectBy Trust39,985 Reported balance Holding disclosure · report date 2025-12-31 · row 6 Holding and transaction disclosures are not merged.
1 source row

Row 6 · Balance 39,985

Filing footnotes · ownership attribution and instrument terms

F1: Each performance restricted stock unit ("PSU") represents a contingent right to receive one share of Company stock. These PSUs were earned during the applicable five-year performance period and vested on December 31, 2025 but remain subject to a mandatory holding period of three years after vesting, which ends early upon the reporting person's death or disability or a change in control of the Company.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
August 16, 2021 Filed Aug 17, 2021 20:42 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 SaleCommon Stock 295 $626.15 $184,714.25
Disclosure

SEC source: 0001708138-21-000058 · edgardoc.xml · nonDerivative · entry 12

SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 33,267

F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

F14 · price: Represents volume-weighted average price of sales of 295 shares of Company stock on August 16, 2021 at prices ranging from $626.04 to $626.63. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 16, 2021 at each separate price.

F3 · ownership.nature: These shares are held in a trust for the benefit of the reporting person's family members. The reporting person's spouse is a trustee of the trust.

Read SEC document
August 16, 2021 Filed Aug 17, 2021 20:42 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 SaleCommon Stock 1,355 $625.19 $847,132.45
Disclosure

SEC source: 0001708138-21-000058 · edgardoc.xml · nonDerivative · entry 11

SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 33,562

F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

F13 · price: Represents volume-weighted average price of sales of 1,355 shares of Company stock on August 16, 2021 at prices ranging from $625.01 to $625.88. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 16, 2021 at each separate price.

F3 · ownership.nature: These shares are held in a trust for the benefit of the reporting person's family members. The reporting person's spouse is a trustee of the trust.

Read SEC document
August 16, 2021 Filed Aug 17, 2021 20:42 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 SaleCommon Stock 1,862 $624.42 $1,162,670.04
Disclosure

SEC source: 0001708138-21-000058 · edgardoc.xml · nonDerivative · entry 10

SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 34,917

F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

F12 · price: Represents volume-weighted average price of sales of 1,862 shares of Company stock on August 16, 2021 at prices ranging from $624.00 to $624.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 16, 2021 at each separate price.

F3 · ownership.nature: These shares are held in a trust for the benefit of the reporting person's family members. The reporting person's spouse is a trustee of the trust.

Read SEC document
August 16, 2021 Filed Aug 17, 2021 20:42 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 SaleCommon Stock 2,393 $623.66 $1,492,418.38
Disclosure

SEC source: 0001708138-21-000058 · edgardoc.xml · nonDerivative · entry 9

SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 36,779

F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

F11 · price: Represents volume-weighted average price of sales of 2,393 shares of Company stock on August 16, 2021 at prices ranging from $623.08 to $623.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 16, 2021 at each separate price.

F3 · ownership.nature: These shares are held in a trust for the benefit of the reporting person's family members. The reporting person's spouse is a trustee of the trust.

Read SEC document
August 16, 2021 Filed Aug 17, 2021 20:42 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 SaleCommon Stock 924 $622.44 $575,134.56
Disclosure

SEC source: 0001708138-21-000058 · edgardoc.xml · nonDerivative · entry 8

SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 39,172

F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

F10 · price: Represents volume-weighted average price of sales of 924 shares of Company stock on August 16, 2021 at prices ranging from $622.00 to $622.84. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 16, 2021 at each separate price.

F3 · ownership.nature: These shares are held in a trust for the benefit of the reporting person's family members. The reporting person's spouse is a trustee of the trust.

Read SEC document
August 16, 2021 Filed Aug 17, 2021 20:42 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 SaleCommon Stock 287 $621.76 $178,445.12
Disclosure

SEC source: 0001708138-21-000058 · edgardoc.xml · nonDerivative · entry 7

SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 40,096

F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

F9 · price: Represents volume-weighted average price of sales of 287 shares of Company stock on August 16, 2021 at prices ranging from $621.25 to $621.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 16, 2021 at each separate price.

F3 · ownership.nature: These shares are held in a trust for the benefit of the reporting person's family members. The reporting person's spouse is a trustee of the trust.

Read SEC document
August 16, 2021 Filed Aug 17, 2021 20:42 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 SaleCommon Stock 96 $620.36 $59,554.56
Disclosure

SEC source: 0001708138-21-000058 · edgardoc.xml · nonDerivative · entry 6

SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 40,383

F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

F8 · price: Represents volume-weighted average price of sales of 96 shares of Company stock on August 16, 2021 at prices ranging from $620.35 to $620.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 16, 2021 at each separate price.

F3 · ownership.nature: These shares are held in a trust for the benefit of the reporting person's family members. The reporting person's spouse is a trustee of the trust.

Read SEC document
August 16, 2021 Filed Aug 17, 2021 20:42 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 SaleCommon Stock 34 $619.83 $21,074.22
Disclosure

SEC source: 0001708138-21-000058 · edgardoc.xml · nonDerivative · entry 5

SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 40,479

F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

F7 · price: Represents volume-weighted average price of sales of 34 shares of Company stock on August 16, 2021 at prices ranging from $619.67 to $619.84. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 16, 2021 at each separate price.

F3 · ownership.nature: These shares are held in a trust for the benefit of the reporting person's family members. The reporting person's spouse is a trustee of the trust.

Read SEC document
August 16, 2021 Filed Aug 17, 2021 20:42 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 SaleCommon Stock 90 $618.82 $55,693.80
Disclosure

SEC source: 0001708138-21-000058 · edgardoc.xml · nonDerivative · entry 4

SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 40,513

F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

F6 · price: Represents volume-weighted average price of sales of 90 shares of Company stock on August 16, 2021 at prices ranging from $618.13 to $618.89. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 16, 2021 at each separate price.

F3 · ownership.nature: These shares are held in a trust for the benefit of the reporting person's family members. The reporting person's spouse is a trustee of the trust.

Read SEC document
August 16, 2021 Filed Aug 17, 2021 20:42 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 SaleCommon Stock 258 $617.79 $159,389.82
Disclosure

SEC source: 0001708138-21-000058 · edgardoc.xml · nonDerivative · entry 3

SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 40,603

F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

F5 · price: Represents volume-weighted average price of sales of 258 shares of Company stock on August 16, 2021 at prices ranging from $617.56 to $617.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 16, 2021 at each separate price.

F3 · ownership.nature: These shares are held in a trust for the benefit of the reporting person's family members. The reporting person's spouse is a trustee of the trust.

Read SEC document
August 16, 2021 Filed Aug 17, 2021 20:42 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 SaleCommon Stock 146 $616.70 $90,038.20
Disclosure

SEC source: 0001708138-21-000058 · edgardoc.xml · nonDerivative · entry 2

SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 40,861

F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

F4 · price: Represents volume-weighted average price of sales of 146 shares of Company stock on August 16, 2021 at prices ranging from $616.66 to $616.73. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 16, 2021 at each separate price.

F3 · ownership.nature: These shares are held in a trust for the benefit of the reporting person's family members. The reporting person's spouse is a trustee of the trust.

Read SEC document
August 16, 2021 Filed Aug 17, 2021 20:42 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 SaleCommon Stock 171 $615.54 $105,257.34
Disclosure

SEC source: 0001708138-21-000058 · edgardoc.xml · nonDerivative · entry 1

SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 41,007

F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

F2 · price: Represents volume-weighted average price of sales of 171 shares of Company stock on August 16, 2021 at prices ranging from $615.35 to $615.79. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 16, 2021 at each separate price.

F3 · ownership.nature: These shares are held in a trust for the benefit of the reporting person's family members. The reporting person's spouse is a trustee of the trust.

Read SEC document
August 06, 2021 Filed Aug 10, 2021 21:05 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative 160,000 $0.00 Strike: $52.03 $0.00
Disclosure

SEC source: 0001708138-21-000048 · edgardoc.xml · derivative · entry 10

SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 160,000 shares

Expires 2021-12-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

F3 · derivative.exercise_date: With respect to 240,000 underlying shares (of which 0 remain outstanding), the option became exercisable on December 31, 2014, based upon the satisfaction by the company of certain performance criteria during the period ended December 31, 2014. With respect to 160,000 underlying shares (of which 0 remain outstanding), the stock option award vested in four equal annual installments, commencing one year after the date of grant.

Read SEC document
August 06, 2021 Filed Aug 10, 2021 21:05 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative 240,000 $0.00 Strike: $52.03 $0.00
Disclosure

SEC source: 0001708138-21-000048 · edgardoc.xml · derivative · entry 9

SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 160,000

Underlying: Common Stock · 240,000 shares

Expires 2021-12-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

F3 · derivative.exercise_date: With respect to 240,000 underlying shares (of which 0 remain outstanding), the option became exercisable on December 31, 2014, based upon the satisfaction by the company of certain performance criteria during the period ended December 31, 2014. With respect to 160,000 underlying shares (of which 0 remain outstanding), the stock option award vested in four equal annual installments, commencing one year after the date of grant.

Read SEC document
August 06, 2021 Filed Aug 10, 2021 21:05 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 Tax withholdingCommon Stock 91,430 $607.51 $55,544,639.30
Disclosure

SEC source: 0001708138-21-000048 · edgardoc.xml · nonDerivative · entry 4

SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 504,746

F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

Read SEC document
August 06, 2021 Filed Aug 10, 2021 21:05 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 Exercise / conversionCommon Stock 160,000 $52.03 $8,324,800.00
Disclosure

SEC source: 0001708138-21-000048 · edgardoc.xml · nonDerivative · entry 3

SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 596,176

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

Read SEC document
August 06, 2021 Filed Aug 10, 2021 21:05 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 Tax withholdingCommon Stock 137,145 $607.51 $83,316,958.95
Disclosure

SEC source: 0001708138-21-000048 · edgardoc.xml · nonDerivative · entry 2

SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 436,176

F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

Read SEC document
August 06, 2021 Filed Aug 10, 2021 21:05 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 Exercise / conversionCommon Stock 240,000 $52.03 $12,487,200.00
Disclosure

SEC source: 0001708138-21-000048 · edgardoc.xml · nonDerivative · entry 1

SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 573,321

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

Read SEC document
May 19, 2021 Filed Aug 10, 2021 21:05 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 GiftCommon Stock 41,178 $0.00 $0.00
Disclosure

SEC source: 0001708138-21-000048 · edgardoc.xml · nonDerivative · entry 6

SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · by 2019 GRAT

Disclosed balance after: 0

Read SEC document
May 19, 2021 Filed Aug 10, 2021 21:05 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 GiftCommon Stock 41,178 $0.00 $0.00
Disclosure

SEC source: 0001708138-21-000048 · edgardoc.xml · nonDerivative · entry 5

SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 41,178

F2 · ownership.nature: These shares are held in a trust for the benefit of the reporting person's family members. The reporting person's spouse is a trustee of the trust.

Read SEC document
December 31, 2020 Filed Jan 5, 2021 21:04 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 GrantPerformance Stock Units · Derivative 620,270 $0.00 $0.00
Disclosure

SEC source: 0001104659-21-000901 · tm211598-1_4seq1.xml · derivative · entry 1

SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 620,270

Underlying: Common Stock · 620,270 shares

Expires not disclosed

F1 · derivative.exercise_price: Each performance restricted stock unit ("PSU") represents a contingent right to receive one share of Company stock. The amount reported is the maximum number of PSUs that may be earned upon achievement of certain total shareholder return ("TSR") goals derived from compound annual growth rates of 5.6% to 19.2% over a five-year performance period ending on December 31, 2025 (or in some cases at earlier times). Between 50% and 250% of the target number of 248,108 PSUs may be earned upon achievement of such TSR goals but shall only vest at the end of the five-year performance period if the reporting person's service to the Company continues through such date, except in certain limited cases (such as if service to the Company is terminated by the Company without cause or in case of a change in control ("CIC")). Earned PSUs are subject to a mandatory holding period of three years after vesting, which ends early upon the reporting person's death or disability or a CIC.

F1 · derivative.exercise_date: Each performance restricted stock unit ("PSU") represents a contingent right to receive one share of Company stock. The amount reported is the maximum number of PSUs that may be earned upon achievement of certain total shareholder return ("TSR") goals derived from compound annual growth rates of 5.6% to 19.2% over a five-year performance period ending on December 31, 2025 (or in some cases at earlier times). Between 50% and 250% of the target number of 248,108 PSUs may be earned upon achievement of such TSR goals but shall only vest at the end of the five-year performance period if the reporting person's service to the Company continues through such date, except in certain limited cases (such as if service to the Company is terminated by the Company without cause or in case of a change in control ("CIC")). Earned PSUs are subject to a mandatory holding period of three years after vesting, which ends early upon the reporting person's death or disability or a CIC.

F1 · derivative.expiration_date: Each performance restricted stock unit ("PSU") represents a contingent right to receive one share of Company stock. The amount reported is the maximum number of PSUs that may be earned upon achievement of certain total shareholder return ("TSR") goals derived from compound annual growth rates of 5.6% to 19.2% over a five-year performance period ending on December 31, 2025 (or in some cases at earlier times). Between 50% and 250% of the target number of 248,108 PSUs may be earned upon achievement of such TSR goals but shall only vest at the end of the five-year performance period if the reporting person's service to the Company continues through such date, except in certain limited cases (such as if service to the Company is terminated by the Company without cause or in case of a change in control ("CIC")). Earned PSUs are subject to a mandatory holding period of three years after vesting, which ends early upon the reporting person's death or disability or a CIC.

Read SEC document
May 12, 2020 Filed May 14, 2020 01:01 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 SaleCommon Stock 638 $577.27 $368,298.26
Disclosure

SEC source: 0001708138-20-000058 · edgardoc.xml · nonDerivative · entry 25

SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 474,499

F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

F22 · price: Represents volume-weighted average price of sales of 638 shares of Company stock on May 12, 2020 at prices ranging from $577.15 to $577.55. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 12, 2020 at each separate price.

Read SEC document
May 12, 2020 Filed May 14, 2020 01:01 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 SaleCommon Stock 1,728 $576.51 $996,209.28
Disclosure

SEC source: 0001708138-20-000058 · edgardoc.xml · nonDerivative · entry 24

SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 475,137

F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

F21 · price: Represents volume-weighted average price of sales of 1,728 shares of Company stock on May 12, 2020 at prices ranging from $576.04 to $576.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 12, 2020 at each separate price.

Read SEC document
May 12, 2020 Filed May 14, 2020 01:01 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 SaleCommon Stock 2,196 $575.48 $1,263,754.08
Disclosure

SEC source: 0001708138-20-000058 · edgardoc.xml · nonDerivative · entry 23

SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 476,865

F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

F20 · price: Represents volume-weighted average price of sales of 2,196 shares of Company stock on May 12, 2020 at prices ranging from $575.04 to $575.85. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 12, 2020 at each separate price.

Read SEC document
May 12, 2020 Filed May 14, 2020 01:01 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 SaleCommon Stock 4,390 $574.59 $2,522,450.10
Disclosure

SEC source: 0001708138-20-000058 · edgardoc.xml · nonDerivative · entry 22

SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 479,061

F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

F19 · price: Represents volume-weighted average price of sales of 4,390 shares of Company stock on May 12, 2020 at prices ranging from $574.17 to $574.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 12, 2020 at each separate price.

Read SEC document
May 12, 2020 Filed May 14, 2020 01:01 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 SaleCommon Stock 10,014 $573.27 $5,740,725.78
Disclosure

SEC source: 0001708138-20-000058 · edgardoc.xml · nonDerivative · entry 21

SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 483,451

F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

F18 · price: Represents volume-weighted average price of sales of 10,014 shares of Company stock on May 12, 2020 at prices ranging from $573.00 to $573.92. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 12, 2020 at each separate price.

Read SEC document
May 12, 2020 Filed May 14, 2020 01:01 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 SaleCommon Stock 19,984 $572.47 $11,440,240.48
Disclosure

SEC source: 0001708138-20-000058 · edgardoc.xml · nonDerivative · entry 20

SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 493,465

F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

F17 · price: Represents volume-weighted average price of sales of 19,984 shares of Company stock on May 12, 2020 at prices ranging from $572.00 to $572.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 12, 2020 at each separate price.

Read SEC document
May 12, 2020 Filed May 14, 2020 01:01 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 SaleCommon Stock 15,542 $571.49 $8,882,097.58
Disclosure

SEC source: 0001708138-20-000058 · edgardoc.xml · nonDerivative · entry 19

SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 513,449

F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

F16 · price: Represents volume-weighted average price of sales of 15,542 shares of Company stock on May 12, 2020 at prices ranging from $571.00 to $571.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 12, 2020 at each separate price.

Read SEC document
May 12, 2020 Filed May 14, 2020 01:01 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 SaleCommon Stock 20,267 $570.49 $11,562,120.83
Disclosure

SEC source: 0001708138-20-000058 · edgardoc.xml · nonDerivative · entry 18

SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 528,991

F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

F15 · price: Represents volume-weighted average price of sales of 20,267 shares of Company stock on May 12, 2020 at prices ranging from $570.01 to $570.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 12, 2020 at each separate price.

Read SEC document
May 12, 2020 Filed May 14, 2020 01:01 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 SaleCommon Stock 19,982 $569.52 $11,380,148.64
Disclosure

SEC source: 0001708138-20-000058 · edgardoc.xml · nonDerivative · entry 17

SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 549,258

F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

F14 · price: Represents volume-weighted average price of sales of 19,982 shares of Company stock on May 12, 2020 at prices ranging from $569.00 to $569.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 12, 2020 at each separate price.

Read SEC document
May 12, 2020 Filed May 14, 2020 01:01 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 SaleCommon Stock 18,021 $568.58 $10,246,380.18
Disclosure

SEC source: 0001708138-20-000058 · edgardoc.xml · nonDerivative · entry 16

SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 569,240

F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

F13 · price: Represents volume-weighted average price of sales of 18,021 shares of Company stock on May 12, 2020 at prices ranging from $568.00 to $568.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 12, 2020 at each separate price.

Read SEC document
May 12, 2020 Filed May 14, 2020 01:01 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 SaleCommon Stock 9,359 $567.57 $5,311,887.63
Disclosure

SEC source: 0001708138-20-000058 · edgardoc.xml · nonDerivative · entry 15

SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 587,261

F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

F12 · price: Represents volume-weighted average price of sales of 9,359 shares of Company stock on May 12, 2020 at prices ranging from $567.00 to $567.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 12, 2020 at each separate price.

Read SEC document
May 12, 2020 Filed May 14, 2020 01:01 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 SaleCommon Stock 5,810 $566.51 $3,291,423.10
Disclosure

SEC source: 0001708138-20-000058 · edgardoc.xml · nonDerivative · entry 14

SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 596,620

F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

F11 · price: Represents volume-weighted average price of sales of 5,810 shares of Company stock on May 12, 2020 at prices ranging from $566.00 to $566.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 12, 2020 at each separate price.

Read SEC document
May 12, 2020 Filed May 14, 2020 01:01 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 SaleCommon Stock 3,032 $565.67 $1,715,111.44
Disclosure

SEC source: 0001708138-20-000058 · edgardoc.xml · nonDerivative · entry 13

SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 602,430

F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

F10 · price: Represents volume-weighted average price of sales of 3,032 shares of Company stock on May 12, 2020 at prices ranging from $565.16 to $565.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 12, 2020 at each separate price.

Read SEC document
May 12, 2020 Filed May 14, 2020 01:01 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 SaleCommon Stock 779 $564.41 $439,675.39
Disclosure

SEC source: 0001708138-20-000058 · edgardoc.xml · nonDerivative · entry 12

SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 605,462

F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

F9 · price: Represents volume-weighted average price of sales of 779 shares of Company stock on May 12, 2020 at prices ranging from $564.01 to $564.69. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 12, 2020 at each separate price.

Read SEC document
May 12, 2020 Filed May 14, 2020 01:01 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 SaleCommon Stock 2,549 $563.51 $1,436,386.99
Disclosure

SEC source: 0001708138-20-000058 · edgardoc.xml · nonDerivative · entry 11

SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 606,241

F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

F8 · price: Represents volume-weighted average price of sales of 2,549 shares of Company stock on May 12, 2020 at prices ranging from $563.12 to $563.85. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 12, 2020 at each separate price.

Read SEC document
May 12, 2020 Filed May 14, 2020 01:01 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 SaleCommon Stock 1,394 $562.75 $784,473.50
Disclosure

SEC source: 0001708138-20-000058 · edgardoc.xml · nonDerivative · entry 10

SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 608,790

F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

F7 · price: Represents volume-weighted average price of sales of 1,394 shares of Company stock on May 12, 2020 at prices ranging from $562.33 to $562.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 12, 2020 at each separate price.

Read SEC document
May 12, 2020 Filed May 14, 2020 01:01 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 SaleCommon Stock 3,994 $561.24 $2,241,592.56
Disclosure

SEC source: 0001708138-20-000058 · edgardoc.xml · nonDerivative · entry 9

SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 610,184

F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

F6 · price: Represents volume-weighted average price of sales of 3,994 shares of Company stock on May 12, 2020 at prices ranging from $561.00 to $561.90. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 12, 2020 at each separate price.

Read SEC document
May 12, 2020 Filed May 14, 2020 01:01 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 SaleCommon Stock 3,391 $560.68 $1,901,265.88
Disclosure

SEC source: 0001708138-20-000058 · edgardoc.xml · nonDerivative · entry 8

SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 614,178

F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

F5 · price: Represents volume-weighted average price of sales of 3,391 shares of Company stock on May 12, 2020 at prices ranging from $560.19 to $560.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 12, 2020 at each separate price.

Read SEC document
May 12, 2020 Filed May 14, 2020 01:01 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 SaleCommon Stock 1,361 $559.52 $761,506.72
Disclosure

SEC source: 0001708138-20-000058 · edgardoc.xml · nonDerivative · entry 7

SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 617,569

F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

F4 · price: Represents volume-weighted average price of sales of 1,361 shares of Company stock on May 12, 2020 at prices ranging from $559.02 to $559.84. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 12, 2020 at each separate price.

Read SEC document
May 12, 2020 Filed May 14, 2020 01:01 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 SaleCommon Stock 4,162 $558.35 $2,323,852.70
Disclosure

SEC source: 0001708138-20-000058 · edgardoc.xml · nonDerivative · entry 6

SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 618,930

F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

F3 · price: Represents volume-weighted average price of sales of 4,162 shares of Company stock on May 12, 2020 at prices ranging from $558.00 to $558.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 12, 2020 at each separate price.

Read SEC document
May 12, 2020 Filed May 14, 2020 01:01 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 SaleCommon Stock 2,329 $557.51 $1,298,440.79
Disclosure

SEC source: 0001708138-20-000058 · edgardoc.xml · nonDerivative · entry 5

SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 623,092

F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

F2 · price: Represents volume-weighted average price of sales of 2,329 shares of Company stock on May 12, 2020 at prices ranging from $557.02 to $557.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 12, 2020 at each separate price.

Read SEC document
May 11, 2020 Filed May 14, 2020 01:01 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative 187,500 $0.00 Strike: $30.63 $0.00
Disclosure

SEC source: 0001708138-20-000058 · edgardoc.xml · derivative · entry 29

SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 187,500 shares

Expires 2020-12-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

F23 · derivative.exercise_date: With respect to 125,000 underlying shares (of which 0 remain outstanding), the stock option award vested in four equal annual installments, commencing one year after the date of grant. With respect to 187,500 underlying shares (of which 0 remain outstanding), the option became exercisable on December 31, 2013, based upon the satisfaction by the company of certain performance criteria during the period ended December 31, 2013.

Read SEC document
May 11, 2020 Filed May 14, 2020 01:01 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative 125,000 $0.00 Strike: $30.63 $0.00
Disclosure

SEC source: 0001708138-20-000058 · edgardoc.xml · derivative · entry 28

SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 187,500

Underlying: Common Stock · 125,000 shares

Expires 2020-12-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

F23 · derivative.exercise_date: With respect to 125,000 underlying shares (of which 0 remain outstanding), the stock option award vested in four equal annual installments, commencing one year after the date of grant. With respect to 187,500 underlying shares (of which 0 remain outstanding), the option became exercisable on December 31, 2013, based upon the satisfaction by the company of certain performance criteria during the period ended December 31, 2013.

Read SEC document
May 11, 2020 Filed May 14, 2020 01:01 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 Tax withholdingCommon Stock 96,947 $571.43 $55,398,424.21
Disclosure

SEC source: 0001708138-20-000058 · edgardoc.xml · nonDerivative · entry 4

SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 625,421

F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

Read SEC document
May 11, 2020 Filed May 14, 2020 01:01 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 Exercise / conversionCommon Stock 187,500 $30.63 $5,743,125.00
Disclosure

SEC source: 0001708138-20-000058 · edgardoc.xml · nonDerivative · entry 3

SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 722,368

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

Read SEC document
May 11, 2020 Filed May 14, 2020 01:01 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 Tax withholdingCommon Stock 64,631 $571.43 $36,932,092.33
Disclosure

SEC source: 0001708138-20-000058 · edgardoc.xml · nonDerivative · entry 2

SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 534,868

F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

Read SEC document
May 11, 2020 Filed May 14, 2020 01:01 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 Exercise / conversionCommon Stock 125,000 $30.63 $3,828,750.00
Disclosure

SEC source: 0001708138-20-000058 · edgardoc.xml · nonDerivative · entry 1

SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 599,499

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

Read SEC document
December 12, 2019 Filed Dec 13, 2019 21:05 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative 187,500 $0.00 Strike: $21.25 $0.00
Disclosure

SEC source: 0001237899-19-000031 · edgardoc.xml · derivative · entry 8

SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 187,500 shares

Expires 2019-12-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

F3 · derivative.exercise_date: The option became exercisable with respect to all shares underlying the option on December 31, 2012, based upon the satisfaction by the company of certain performance criteria during the period ended December 31, 2012.

Read SEC document
December 12, 2019 Filed Dec 13, 2019 21:05 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative 124,900 $0.00 Strike: $21.25 $0.00
Disclosure

SEC source: 0001237899-19-000031 · edgardoc.xml · derivative · entry 7

SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 187,500

Underlying: Common Stock · 124,900 shares

Expires 2019-12-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

F2 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.